Patents by Inventor Glen Ernst

Glen Ernst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11993581
    Abstract: Pyridazine compounds for inhibiting NaV1.8 and methods for treating a condition, disease, or disorder associated with an increased NaV1.8 activity or expression are disclosed.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: May 28, 2024
    Assignee: LIEBER INSTITUE, INC
    Inventors: Michael Poslusney, Glen Ernst, James Barrow
  • Publication number: 20220227732
    Abstract: Pyridine carboxamide compounds for inhibiting NaV1.8 and methods for treating a condition, disease, or disorder associated with an increased NaV1.8 activity or expression are disclosed.
    Type: Application
    Filed: July 9, 2019
    Publication date: July 21, 2022
    Inventors: Michael Poslusney, Glen Ernst, James Barrow, Yifang Huang
  • Publication number: 20210261542
    Abstract: RNA polymerase I (Pol I) is a dedicated polymerase for the transcription of the 47S ribosomal RNA precursor subsequently processed into the mature 5.8S, 18S and 28S ribosomal RNAs and assembled into ribosomes in the nucleolus. Pol I activity is commonly deregulated in human cancers. Based on the discovery of lead molecule BMH-21, a series of pyridoquinazolinecarboxamides were synthesized as inhibitors of Pol I and activators of the destruction of RPA194, the Pol I large catalytic subunit protein. The present invention identifies a set of bioactive compounds, including purified stereoisomers, that potently cause RPA194 degradation that function in a tightly constrained chemical space. Pharmaceutical compositions comprising these compounds and their uses in cancer and other Pol I related diseases is also provided.
    Type: Application
    Filed: March 8, 2021
    Publication date: August 26, 2021
    Inventors: Marikki Laiho, Laureen Colis, James C. Barrow, Glen Ernst, Sara Sanders
  • Publication number: 20210139479
    Abstract: This invention relates to compounds, pharmaceutical compositions and their use for treating neuropsychiatric and neurodegenerative disorders. In particular, the invention relates to inhibitors of catechol-O-methyltransferase and their use as therapeutics for central nervous system disease.
    Type: Application
    Filed: January 22, 2021
    Publication date: May 13, 2021
    Inventors: James Barrow, Glen Ernst, Dominique Swinnen, Florian Montel, Sabine Defays, Yifeng Huang, Pablo de Leon, Michael Steven Poslusney
  • Publication number: 20210139456
    Abstract: Pyridazine compounds for inhibiting NaV1.8 and methods for treating a condition, disease, or disorder associated with an increased NaV1.8 activity or expression are disclosed.
    Type: Application
    Filed: July 9, 2019
    Publication date: May 13, 2021
    Inventors: Michael Poslusney, Glen Ernst, James Barrow
  • Patent number: 11001581
    Abstract: RNA polymerase I (Pol I) is a dedicated polymerase for the transcription of the 47S ribosomal RNA precursor subsequently processed into the mature 5.8S, 18S and 28S ribosomal RNAs and assembled into ribosomes in the nucleolus. Pol I activity is commonly deregulated in human cancers. Based on the discovery of lead molecule BMH-21, a series of pyridoquinazolinecarboxamides were synthesized as inhibitors of Pol I and activators of the destruction of RPA194, the Pol I large catalytic subunit protein. The present invention identifies a set of bioactive compounds, including purified stereoisomers, that potently cause RPA194 degradation that function in a tightly constrained chemical space. Pharmaceutical compositions comprising these compounds and their uses in cancer and other Pol I related diseases is also provided.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: May 11, 2021
    Assignee: The Johns Hopkins University and Lieber Institute, Inc.
    Inventors: Marikki Laiho, Laureen Colis, James C. Barrow, Glen Ernst, Sara Sanders
  • Patent number: 10934283
    Abstract: Compounds that inhibit COMT enzyme and pharmaceutical compositions comprising the same are provided herein. Methods of treating various psychiatric and neurological disorders with the compounds and pharmaceutical compositions described herein are also provided.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: March 2, 2021
    Assignee: LIEBER INSTITUTE, INC.
    Inventors: James Barrow, Glen Ernst, Dominique Swinnen, Florian Montel, Sabine Defays, Yifang Huang, Pablo de León, Michael Steven Poslusney
  • Patent number: 10479790
    Abstract: The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: November 19, 2019
    Assignee: LIEBER INSTITUTE FOR BRAIN DEVELOPMENT
    Inventors: James Barrow, Glen Ernst, Yifang Huang, Ingrid Price Buchler, Daniel Weinberger
  • Publication number: 20180305360
    Abstract: The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.
    Type: Application
    Filed: June 26, 2018
    Publication date: October 25, 2018
    Inventors: James Barrow, Glen Ernst, Yifang Huang, Ingrid Price Buchler, Daniel Weinberger
  • Publication number: 20180305354
    Abstract: Compounds that inhibit COMT enzyme and pharmaceutical compositions comprising the same are provided herein. Methods of treating various psychiatric and neurological disorders with the compounds and pharmaceutical compositions described herein are also provided.
    Type: Application
    Filed: November 25, 2016
    Publication date: October 25, 2018
    Inventors: James Barrow, Glen Ernst, Dominique Swinnen, Florian Montel, Sabine Defays, Yifang Huang, Pablo de LEÓN, Michael Steven Poslusney
  • Patent number: 10035799
    Abstract: The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: July 31, 2018
    Assignee: LIEBER INSTITUTE FOR BRAIN DEVELOPMENT
    Inventors: James Barrow, Glen Ernst, Yifang Huang, Ingrid Price Buchler, Daniel Weinberger
  • Patent number: 9951057
    Abstract: The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: April 24, 2018
    Assignee: LIEBER INSTITUTE FOR BRAIN DEVELOPMENT
    Inventors: James Barrow, Glen Ernst, Yifang Huang, Ingrid Price Buchler, Daniel Weinberger
  • Publication number: 20170081322
    Abstract: RNA polymerase I (Pol I) is a dedicated polymerase for the transcription of the 47S ribosomal RNA precursor subsequently processed into the mature 5.8S, 18S and 28S ribosomal RNAs and assembled into ribosomes in the nucleolus. Pol I activity is commonly deregulated in human cancers. Based on the discovery of lead molecule BMH-21, a series of pyridoquinazolinecarboxamides were synthesized as inhibitors of Pol I and activators of the destruction of RPA194, the Pol I large catalytic subunit protein. The present invention identifies a set of bioactive compounds, including purified stereoisomers, that potently cause RPA194 degradation that function in a tightly constrained chemical space. Pharmaceutical compositions comprising these compounds and their uses in cancer and other Pol I related diseases is also provided.
    Type: Application
    Filed: March 20, 2015
    Publication date: March 23, 2017
    Inventors: Marikki Laiho, Laureen Colis, James C. Barrow, Glen Ernst, Sarah Sanders
  • Publication number: 20160222011
    Abstract: The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.
    Type: Application
    Filed: January 29, 2016
    Publication date: August 4, 2016
    Inventors: James Barrow, Glen Ernst, Yifang Huang, Ingrid Price Buchler, Daniel Weinberger
  • Publication number: 20160222001
    Abstract: The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.
    Type: Application
    Filed: January 29, 2016
    Publication date: August 4, 2016
    Inventors: James Barrow, Glen Ernst, Yifang Huang, Ingrid Price Buchler, Daniel Weinberger
  • Patent number: 7977355
    Abstract: N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, pharmaceutically acceptable salts thereof, and/or mixtures thereof, as well as, pharmaceutical compositions thereof, methods of treatment therewith, and processes of making N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide and intermediates thereof.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: July 12, 2011
    Assignee: Astrazeneca AB
    Inventors: Megan Murphy King, Cathy Dantzman, Glen Ernst, Thomas J. Hudzik, Khanh Bui
  • Publication number: 20100160374
    Abstract: N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, pharmaceutically acceptable salts thereof, and/or mixtures thereof, as well as, pharmaceutical compositions thereof, methods of treatment therewith, and processes of making N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide and intermediates thereof.
    Type: Application
    Filed: December 21, 2009
    Publication date: June 24, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Khanh Bui, Cathy Dantzman, Glen Ernst, Valerie Hoesch, Thomas Hudzik, Megan Murphy King, Jie Liu, Jingbo Yan
  • Patent number: 7659286
    Abstract: N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, pharmaceutically acceptable salts thereof, and/or mixtures thereof, as well as, pharmaceutical compositions thereof, methods of treatment therewith, and processes of making N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide and intermediates thereof.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: February 9, 2010
    Assignee: AstraZeneca AB
    Inventors: Cathy Dantzman, Glen Ernst, Megan Murphy King
  • Patent number: 7482338
    Abstract: Compounds of Formula I: and pharmaceutically-acceptable salts thereof, wherein Q, E and D are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them and uses of them for diagnostic and analytic purposes.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: January 27, 2009
    Assignee: AstraZeneca AB
    Inventors: Glen Ernst, Eifion Phillips, Richard J Schmiesing
  • Publication number: 20080182875
    Abstract: N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, pharmaceutically acceptable salts thereof, and/or mixtures thereof, as well as, pharmaceutical compositions thereof, methods of treatment therewith, and processes of making N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide and intermediates thereof.
    Type: Application
    Filed: October 19, 2007
    Publication date: July 31, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Khanh Bui, Cathy Dantzman, Glen Ernst, Valerie Hoesch, Thomas Hudzik, Megan Murphy King, Jie Liu, Jingbo Yan